Login to Your Account

Cardiome Expanding Pipeline Through Artesian Acquisition

By Aaron Lorenzo

Tuesday, August 30, 2005
Just weeks after reporting poor Phase II data on a congestive heart failure drug, Cardiome Pharma Corp. unveiled plans to expand its portfolio by acquiring Artesian Therapeutics Inc. in a deal that could be worth $64 million. But right now, the buyout won't affect the bottom line, as the final value is contingent on the clinical success of two investigational drugs. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription